Rx-to-OTC switches of asthma drugs
Executive Summary
Will be discussed by FDA's Nonprescription Drugs and Pulmonary-Allergy Drugs Advisory Committees during joint meeting Nov. 14. As part of broader discussion of OTC anti-asthma products, committee will discuss "anti-asthma drug products currently available by prescription only that could be considered for OTC status" and "data requirements necessary to support conversion of prescription anti-asthma drug products to OTC." In July 7 Federal Register notice, FDA announces availability of background document for the committee meeting. The meeting will take place at FDA's Parklawn building, conference rooms G through J, beginning at 8:30 a.m